ABOUT / PARTNERS
Partnering at pSivida
As a leader in the development of miniaturized, sustained-release drug delivery systems, pSivida has successfully created partnerships with some of the world's leading pharmaceutical companies. pSivida seeks strategic partnerships to accelerate development of our existing product pipeline; to access complementary research, technology and development capabilities; and to expand our product portfolio. We seek to combine our strengths with other organizations and work collaboratively to develop and commercialize therapeutic products and devices.
Bausch & Lomb
pSivida has licensed two FDA approved products and their underlying technologies to Bausch & Lomb Incorporated: Retisert for the treatment of posterior uveitis and Vitrasert for the treatment of AIDS-related cytomegalovirus (CMV) retinitis.
pSivida has licensed ILUVIEN® to Alimera Sciences for certain ophthalmic applications. ILUVIEN, our most recently approved product, has been granted marketing authorization in the UK, Austria, France, Germany, Portugal, Spain, Italy, Norway and Denmark for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
pSivida has a worldwide collaborative research and license agreement with Pfizer Inc. focused on developing a long-term, sustained release implant to deliver latanoprost to treat patients with ocular hypertension and glaucoma.
pSivida's technologies have broad applicability across therapeutic areas. Our powerful and validated technologies can be utilized to deliver new drugs or to repurpose existing molecules in new applications. pSivida's intellectual property portfolio consists of over 190 patents either issued or granted for acceptance, over 175 pending applications and 60 patent families. We evaluate opportunities where we may collaborate with partners to commercialize and/or co-develop therapeutic products utilizing our technologies.
For more information regarding partnering with pSivida, contact: